Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer
Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
Pembrolizumab/Chemo Earns European Approval in Resectable NSCLC
Data from the phase 3 KEYNOTE-671 trial support the European Commission’s approval of pembrolizumab plus chemotherapy for those with resectable non–small cell lung cancer.
Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope
Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.
Revumenib Receives FDA Priority Review in R/R KMT2Ar Acute Leukemia
Data from the phase 2 AUGMENT-101 trial support the biologics license application for revumenib in patients with relapsed/refractory KMT2A-rearranged acute leukemia.
Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study
Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.